Final overall survival results show amivantamab plus lazertinib beat out osimertinib for first-line treatment of advanced ...

Cancer remains a leading cause of death globally, with lung cancer being particularly lethal. Despite advancements in diagnostics and therapies, the five-year survival rates for advanced tumors have ...

A recent study published in Engineering has shed new light on the mechanisms underlying the metastasis of head and neck ...

The first-line combination of amivantamab-vmjw plus lazertinib extended OS compared with osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer, according to data from the ...

Odontogenic myxoma (OM) is a rare benign tumor originating from the odontogenic mesenchyme, characterized by locally aggressive behavior in the jaw bones. We present a case report of a 36-year-old ...

Ernexa Therapeutics embarks on new strategic direction, shifting the company’s focus from delivering a cell therapy platform to prioritizing product development New tagline to emphasize the company’s ...

Researchers are studying how exercise influences breast cancer progression. Their findings show that physical activity can ...

In the stroma of ovarian cancer, a type of progenitor cell normally involved in the growth and repair of healthy tissue ...

Researchers at the University of Pittsburgh have found special high-risk cells in the fallopian tubes that may trigger ...

Ovarian cancer is the deadliest form of gynecologic cancer, taking the lives of more than 13,000 women in the U.S. each year. The most common type, high-grade serous ovarian carcinoma (HGSOC), is ...

Researcher suggests compounds secreted by high-risk MSCs that are detectable in the bloodstream could act as biomarkers for ...

Researchers at the University of Pittsburgh have identified a novel trigger of a deadly form of ovarian cancer: a subset of ...